Ποια είναι η τιμή για Celltrion, Inc. (068270)

Η τιμή για Celltrion, Inc. (068270) είναι $132.84

Ποια είναι η κεφαλαιοποίηση αγοράς για Celltrion, Inc. (068270)

Η κεφαλαιοποίηση αγοράς για Celltrion, Inc. (068270) είναι $30.46B

Celltrion, Inc. (068270) Τιμή και Κεφαλαιοποίηση Αγοράς

Celltrion, Inc., a South Korean biopharmaceutical company, specializes in the development and manufacturing of protein-based therapies, including treatments for oncology. Its commercial portfolio features established products such as Remsima, Truxima, and Herzuma, alongside a range of generic pharmaceuticals and diagnostic kits for COVID-19. The company maintains an extensive pipeline of antibody biosimilars currently undergoing various stages of clinical evaluation. Late-stage (Phase 3) candidates include CT-P17, aimed at rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease (IBD); CT-P16, targeting metastatic colorectal and breast cancers; CT-P43, for inflammatory conditions like psoriasis, Crohn's disease, and ulcerative colitis; CT-P42, addressing diabetic macular edema; and CT-P59, developed for COVID-19. In Phase 2, CT-P27 is being tested for pandemic and seasonal influenza. Earlier in development, Phase 1 assets comprise CT-P39 for asthma and urticaria, CT-P41 for osteoporosis and bone loss, and CT-G20 for cardiomyopathy. Additionally, Celltrion maintains a collaboration with Inhalon Biopharma, Inc. to advance IN-006, an inhaled formulation of regdanvimab intended for the treatment of COVID-19 patients. Established in 2002, the company operates primarily from its headquarters in Incheon, South Korea.

Η τιμή για 068270	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$22,034.48 $30.46B	NVDA	$5.053T	+16,487.74%
$19,903.39 $30.46B	AAPL	$4.564T	+14,883.44%
$18,294.83 $30.46B	GOOG	$4.196T	+13,672.51%
$15,824.94 $30.46B	MSFT	$3.629T	+11,813.15%
$12,302.36 $30.46B	AMZN	$2.821T	+9,161.32%

Η τιμή για 068270

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$22,034.48 $30.46B